Appendix B. Examples of brief and more extensive guideline recommendations for older people according to the three criteria for CPG recommendations older people.

<table>
<thead>
<tr>
<th>Guideline name</th>
<th>Guideline developer</th>
<th>Available evidence</th>
<th>Practical tip. For patients older than 75 years of age, the Framingham model is not well validated.</th>
<th>Estimating risk: The evidence base to inform recommendations for lipid lowering in primary prevention in the elderly is limited. An assessment of the balance between the harms and benefits of treatment is more difficult in older than in younger people. Older people gain a similar relative benefit from cholesterol lowering, but are more likely to benefit in absolute terms (over the same time period) because of their much higher pre-treatment of cardiovascular risk.</th>
<th>Box 13 Antihypertensive treatment in the elderly</th>
</tr>
</thead>
<tbody>
<tr>
<td>4th Edition of Clinical Practice Guidelines: Management of Dyslipidemia 2011 [1]</td>
<td>Ministry of Health, Malaysia</td>
<td>Increasing age is a major risk factor for CVD and death. (...) The benefits of lipid lowering therapy for primary prevention in elderly individuals with no other risk factors besides dyslipidaemia are less well established</td>
<td></td>
<td></td>
<td>- Randomized trials in patients with systolic-diastolic or isolated systolic hypertension aged ≥ 60 years have shown that a marked reduction in cardiovascular morbidity and mortality can be achieved with antihypertensive treatment</td>
</tr>
<tr>
<td>2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult [2]</td>
<td>Canadian Cardiovascular Society</td>
<td></td>
<td></td>
<td></td>
<td>- Drug treatment can be initiated with thiazide diuretics, calcium antagonists, angiotensin receptor antagonists, ACE inhibitors, and b-blockers, in line with general guidelines. Trials specifically addressing treatment of isolated systolic hypertension have shown the benefit of thiazides and calcium antagonists but subanalysis of other trials also shows efficacy of angiotensin receptor</td>
</tr>
</tbody>
</table>

**Guideline name**
- New Zealand Primary Care Handbook 2012 (updated 2013): Cardiovascular Disease Risk Assessment [3]

**Guideline developer**
- Ministry of Health, Malaysia
- Canadian Cardiovascular Society
- New Zealand Guidelines Group
- European Society of Cardiology

**Available evidence**
- Increasing age is a major risk factor for CVD and death. (...) The benefits of lipid lowering therapy for primary prevention in elderly individuals with no other risk factors besides dyslipidaemia are less well established
- Practical tip. For patients older than 75 years of age, the Framingham model is not well validated.
- Estimating risk: The evidence base to inform recommendations for lipid lowering in primary prevention in the elderly is limited. An assessment of the balance between the harms and benefits of treatment is more difficult in older than in younger people. Older people gain a similar relative benefit from cholesterol lowering, but are more likely to benefit in absolute terms (over the same time period) because of their much higher pre-treatment of cardiovascular risk.

**Box 13 Antihypertensive treatment in the elderly**
- Randomized trials in patients with systolic-diastolic or isolated systolic hypertension aged ≥ 60 years have shown that a marked reduction in cardiovascular morbidity and mortality can be achieved with antihypertensive treatment
- Drug treatment can be initiated with thiazide diuretics, calcium antagonists, angiotensin receptor antagonists, ACE inhibitors, and b-blockers, in line with general guidelines. Trials specifically addressing treatment of isolated systolic hypertension have shown the benefit of thiazides and calcium antagonists but subanalysis of other trials also shows efficacy of angiotensin receptor
| Barriers to implementation | Global risk assessment using standard risk factors as mentioned earlier is generally less reliable in older persons | One approach is extrapolation of the modified FRS, and this approach identifies most subjects as having intermediate-to high-risk based on age | An assessment of the balance between the harms and benefits of treatment is more difficult in older than in younger people. Older people gain a similar relative benefit from cholesterol lowering, but are more likely to benefit in absolute terms (over the same time period) because of their much higher pre-treatment of cardiovascular risk. However, comorbidity is more common and the time available to derive benefit will be shorter. | Initial doses and subsequent dose titration should be more gradual because of a greater chance of undesirable effects, especially in very old and frail subjects. BP goal is the same as in younger patients, i.e. $<140/90$ mmHg or below, if tolerated. Many elderly patients need two or more drugs to control blood pressure and reductions to $<140$ mmHg systolic may be particularly difficult to obtain. Drug treatment should be tailored to the risk factors, target organ damage and associated cardiovascular and non-cardiovascular conditions that are frequent in the elderly. Because of the increased risk of postural hypotension, BP should always be measured also in the erect posture. |
| **Tailoring to older patient** | Clinical judgment and consideration of co-morbid factors, co-existing disease and functional age become essential in deciding the need for drug therapy in this situation. | Though clinical studies are currently under way to address this group, at this point clinical judgment is required in consultation with the patient to determine the value of pharmacotherapy. | However, comorbidity is more common and the time available to derive benefit will be shorter. Similarly, the patient’s expectations should be taken into account in the shared decisions. Smoking cessation is beneficial at any age. | Drug treatment should be tailored to the risk factors, target organ damage and associated cardiovascular and non-cardiovascular conditions that are frequent in the elderly. |
REFERENCES